DiaMedica Therapeutics (DMAC) Total Liabilities (2017 - 2026)

DiaMedica Therapeutics has reported Total Liabilities for 10 years, with the latest figure at $5.8 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities rose 19.87% year-over-year to $5.8 million; the trailing twelve-month figure through Mar 2026 stood at $5.8 million (up 19.87% YoY), and the FY2025 full-year result was $5.3 million, down 6.52% from the prior year.
• Total Liabilities for Q1 2026 stood at $5.8 million, up from $5.3 million in the prior quarter.
• The five-year high for Total Liabilities was $5.8 million in Q1 2026, with the low at $1.4 million in Q1 2022.
• Historically, Total Liabilities has averaged $3.6 million across 5 years, with a median of $3.2 million in 2023.
• Annual changes were most pronounced in 2023 — Total Liabilities surged 121.41% — and 2024, when it dropped 8.89%.
• DiaMedica Therapeutics' Total Liabilities stood at $2.6 million in 2022, then increased by 20.83% to $3.1 million in 2023, then soared by 81.34% to $5.6 million in 2024, then decreased by 6.52% to $5.3 million in 2025, then increased by 11.12% to $5.8 million in 2026.
• The last three Total Liabilities figures came in at $5.8 million (Q1 2026), $5.3 million (Q4 2025), and $5.4 million (Q3 2025), per Business Quant data.